Abstract 38P
Background
Patients who reach pathological complete remission (PCR) after neoadjuvant therapy for triple-negative breast cancer (TNBC) have a better overall prognosis and do not require additional adjuvant therapy postoperatively according to current guidelines; however, some patients still have a lower survival rate.
Methods
We identified TNBC patients who completed neoadjuvant therapy and achieved PCR registered in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. We analyzed the relationship between clinicopathological characteristics and overall survival, seeking to explore the high-risk factors for poor prognosis in patients who achieved PCR after neoadjuvant therapy for TNBC.
Results
A total of 1237 TNBC patients without distant metastases completed neoadjuvant therapy and achieved PCR, and their 5-year overall survival rate was 90.78%. We incorporated age, TNM stage (AJCC 7th edition), and presence of lymph node metastasis as variables to construct a multifactorial COX proportional risk model. The results found no statistically significant effect on survival time in stage II patients compared to stage I patients (HR=1.057, 95%CI 0.540-2.069, P=0.872), but statistically significant compared to stage III patients (HR=2.441, 95%CI 1.159-5.144, P=0.019). There was a statistically significant effect on survival time in patients with lymph node metastases compared to those without lymph node metastases (HR=1.913, 95%CI 1.253-2.921, P=0.003); and no statistically significant effect on survival time in patients younger than 40 years compared to those older than 40 years (HR=1.190, 95%CI 0.615-2.302, P= 0.605).
Conclusions
Younger age is not a factor influencing the prognosis of TNBC patients with PCR. For patients with stage III or lymph node metastases, even if PCR is achieved, further adjuvant therapy may be needed to improve prognosis. The type of adjuvant therapy to be used may need to be further confirmed by future prospective clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract